Comparative Pharmacology
Head-to-head clinical analysis: ADRUCIL versus GEMCITABINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADRUCIL versus GEMCITABINE HYDROCHLORIDE.
ADRUCIL vs GEMCITABINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorouracil (5-FU) is a pyrimidine analog that inhibits thymidylate synthase, interfering with DNA synthesis. It is metabolized to its active metabolites, which incorporate into RNA and DNA, causing cytotoxicity primarily in S-phase cells.
Gemcitabine is a nucleoside analog that inhibits DNA synthesis. It is phosphorylated intracellularly to active diphosphate and triphosphate metabolites. The diphosphate inhibits ribonucleotide reductase, reducing deoxynucleotide pools, while the triphosphate competes with deoxycytidine triphosphate for incorporation into DNA, causing masked chain termination and apoptosis.
12 mg/kg IV bolus daily for 4 days, then if no toxicity, 6 mg/kg IV on days 6, 8, 10, and 12; or 15 mg/kg IV weekly; or 500-600 mg/m2 IV every 3-4 weeks.
1000 mg/m² IV over 30 minutes on days 1 and 8 of a 21-day cycle, or 1250 mg/m² IV over 30 minutes on days 1 and 8 of a 21-day cycle.
None Documented
None Documented
Biphasic elimination: initial t1/2α ~10-20 minutes, terminal t1/2β ~20-24 hours. Accumulation occurs with continuous infusion.
Short terminal half-life (~8-17 min) for parent drug; prolonged 14-18 h for triphosphate active metabolite intracellularly in peripheral blood mononuclear cells; clinical context necessitates prolonged infusion schedules.
Primarily hepatic metabolism; renal excretion of metabolites accounts for ~60-80% of the dose. Unchanged fluorouracil excreted renally is <10%. Fecal excretion is minimal (<5%).
Primarily renal: 92-98% of administered dose excreted unchanged in urine; <1% excreted in feces; <5% as inactive metabolite 2',2'-difluorodeoxyuridine.
Category C
Category D/X
Antimetabolite
Antimetabolite